NCT00061672已完成2 期
A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 67
- 试验地点
- 27
- 主要终点
- Response rate
研究概览
简要总结
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A subject will be eligible for study participation if all of the following criteria are met:
- •The subject is at least 18 years of age.
- •The subject has histologically confirmed non-Hodgkin's Lymphoma (NHL) (excluding Burkitt's, Burkitt's type or HIV associated lymphoma) or Hodgkin's Lymphoma (HL) that is refractory to or has relapsed after standard therapy or for which there is no known effective treatment.
- •The subject must have measurable disease by the CHESON Criteria for Tumor Response.
- •The subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-
- •The subject is able to self-administer or has a caregiver who can reliably administer subcutaneous injections.
- •The subject must have adequate bone marrow, renal and hepatic function as follows:
- •Bone marrow: *White blood cell count (WBC) greater than or equal to 3,000/mm3; *Platelets greater than or equal to 75,000/mm3 unless subject has received a prior transplant or bone marrow involvement with lymphoma has been documented, then platelets of equal to or greater than 50,000 is acceptable. *Hemoglobin greater than or equal to 8.5 g/dL; *ANC greater than or equal to 1000/mm3
- •Renal function: *Serum creatinine less than or equal to 2.0 mg/dL
- •Hepatic function: *AST and ALT less than or equal to 3.0 X ULN
- •The subject must not be pregnant or lactating and all subjects (male and female) must use a contraceptive method deemed appropriate by the investigator while in the study and up to two months following completion of therapy.
- •The subject has voluntarily signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent prior to any study specific procedures.
排除标准
- •A subject will be ineligible for study participation if any of the following criteria are met:
- •The subject has a history of or currently exhibits Central Nervous System (CNS) metastasis. Brain MRI within 28 days of enrollment is required to confirm absence of CNS metastases.
- •The subject is receiving therapeutic anticoagulation therapy. Low dose anticoagulation (e.g., low dose Coumadin) for catheter prophylaxis is permitted; PT/PTT must be within normal limits.
- •The subject has a history of or currently exhibits clinically significant cancer related events of bleeding (e.g., hemoptysis). The subject has a recent history of (within 4 weeks of Study Day 1) or currently exhibits other clinically significant events of bleeding.
- •The subject has received any therapy for lymphoma including chemotherapy, antibody therapy, radiotherapy or any investigational therapy within four weeks prior to study drug administration.
- •The subject has been initiated on steroids or there is an increase in current steroid dose within three months prior to study drug administration.
- •The subject exhibits evidence of clinically significant uncontrolled condition(s) and/or is considered by the investigator to be unable to tolerate the proposed treatment or procedures.
- •The subject has history of other previous malignancies within 5 years, with the exception of: Adequately treated in situ carcinoma of the cervix; Basal or squamous cell carcinoma of the skin.
结局指标
主要结局
Response rate
时间窗: One year
次要结局
- Progression free survival(One year)
- Overall survival(One year)
- Performance status(One year)
研究者
研究点 (27)
Loading locations...
相似试验
已完成
2 期
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue SarcomaSarcoma, Soft TissueNCT00061659Abbott88
已完成
2 期
Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell CarcinomaCarcinoma, Renal CellNCT00073125Abbott103
已完成
2 期
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant RecipientsChronic Hepatitis C InfectionNCT01782495AbbVie129
已完成
1 期
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid TumorsSolid TumorsNCT00586092Herbert Hurwitz45
Unknown
2 期
HPTN 081 AMP StudyHIV/AIDSPACTR202005582198497Division of AIDS82